文献速递造血干细胞移植与细胞治疗

评估阿巴西普治疗激素难治性慢性移植物抗宿主病的1期临床试验

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
PubMed 文献 · Blood · 2018-03-16

这项1期临床试验采用3+3设计,评估阿巴西普3 mg/kg与10 mg/kg两个递增剂量(扩展队列用10 mg/kg)治疗激素难治性慢性移植物抗宿主病的安全性与疗效。16例可评估患者中44%按2005年美国国立卫生研究院共识标准达到临床部分缓解,临床缓解者泼尼松用量平均降低51.3%(基线均值27 mg vs 14 mg,P = .01)。

要点

  • 阿巴西普耐受良好,未观察到剂量限制性毒性。
  • 16例可评估患者中44%达到临床部分缓解。
  • 临床缓解者泼尼松用量平均降低51.3%(27 mg vs 14 mg,P = .01)。

核心结论

  • 阿巴西普安全,并使美国国立卫生研究院cGVHD评分明显改善、泼尼松用量显著减少。
  • 在这组经重度预处理的患者中,结果提示阿巴西普可能是激素难治性慢性移植物抗宿主病有前景的治疗药物,2期试验已启动。

研究设计与样本

  • 1期临床试验,采用3+3设计,设阿巴西普3 mg/kg与10 mg/kg两个递增剂量,并设10 mg/kg扩展队列。
  • 共16例可评估患者。
  • 试验注册号为NCT01954979。

主要发现

  • 阿巴西普耐受良好,无剂量限制性毒性。
  • 16例可评估患者中44%按2005年美国国立卫生研究院共识标准达到临床部分缓解。
  • 临床缓解者泼尼松用量平均降低51.3%(基线均值27 mg vs 14 mg,P = .01)。
  • 临床缓解者循环CD4 T细胞PD-1表达升高(P = .009),CD8 T细胞PD-1表达升高(P = .007)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Steroid-refractory chronic graft-versus-host disease (SR-cGVHD) remains a major cause of morbidity and mortality after allogeneic stem cell transplantation. Innovative immunotherapeutic strategies are urgently needed for the treatment of SR-cGVHD. We conducted a phase 1 clinical trial to evaluate the safety, efficacy, and immune effects of abatacept, a novel immunomodulatory drug that acts as an inhibitor of T-cell activation via costimulatory blockade, in the treatment of SR-cGVHD. The study followed a 3+3 design with 2 escalating abatacept doses: 3 mg/kg and 10 mg/kg, with an expansion cohort treated at 10 mg/kg. Abatacept was well-tolerated with no dose-limiting toxicities. Of the 16 evaluable patients, 44% achieved a clinical partial response per 2005 National Institutes of Health Consensus Criteria. Importantly, abatacept resulted in a 51.3% reduction in prednisone usage in clinical responders (mean baseline, 27 vs 14 mg; P = .01). Increased PD-1 expression on circulating CD4 (P = .009) and CD8 (P = .007) T cells was observed in clinical responders. In summary, abatacept was safe and led to a marked improvement in National Institutes of Health cGVHD scores and a significant reduction in prednisone use. In this cohort of heavily pretreated patients, the results suggest abatacept may be a promising therapeutic agent for SR-cGVHD, and a phase 2 trial has been initiated. This trial was registered at www.clinicaltrials.gov as #NCT01954979.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nahas MR, Soiffer RJ, Kim HT, et al. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018. PMID: 29549175. doi:10.1182/blood-2017-05-780239

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。